Molecular mechanisms and its clinical impact in cancer cachexia;Molekulare Mechanismen und klinische Auswirkungen der Tumorkachexie

Zeitschrift fur Gastroenterologie

Volumn 46, Issue 12, 2008, Pages 1384-1392

  Bachmann, J ^a   Friess, H ^a   Martignoni, M E ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cachexia; Loss of weight; Pancreatic cancer; Survival

Indexed keywords

DRONABINOL; GAMMA INTERFERON; IBUPROFEN; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 6; MIANSERIN; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; PROTEASOME; THALIDOMIDE; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

ANOREXIA; ARTICLE; CACHEXIA; DISEASE COURSE; HUMAN; LIPID METABOLISM; LIPOLYSIS; MALNUTRITION; PANCREAS CANCER; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; QUALITY OF LIFE; SURVIVAL; WEIGHT REDUCTION;

CACHEXIA; CYTOKINES; HUMANS; LIPASE; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEOGLYCANS; SIGNAL TRANSDUCTION; SURVIVAL RATE; UBIQUITIN;

EID: 58149477390     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027655     Document Type: Article

References (92)

1. Camps C, Iranzo V, Bremnes RM et al. Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway. Support Care Cancer 2006; 14(12): 1173-1183
2. Barber MD, Ross JA, Fearon KC. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer 1999; 35: 106-110
3. Karthaus M, Frieler F. Eating and drinking at the end of life. Nutritional support for cancer patients in palliative care. Wien Med Wochenschr 2004; 154: 192-198
4. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 2005; 8: 265-269
5. Bossola M, Pacelli F, Tortorelli A et al. Cancer Cachexia: It's Time for More Clinical Trials. Ann Surg Oncol 2007; 14: 276-285
6. Laviano A, Meguid MM, Inui A et al. Therapy insight: Cancer anorexia-cachexia syndrome - when all you can eat is yourself. Nat Clin Pract Oncol 2005; 2: 158-165
7. Dewys WD, Begg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69: 491-497
8. Baldwin C, Parsons T, Logan S. Dietary advice for illness-related malnutrition in adults. Cochrane Database Syst Rev 2001; (2): CD002008
9. Uomo G, Galluci F, Rabitti P. Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management. JOP 2006; 7: 157-162
10. Tisdale MJ. Cancer anorexia and cachexia. Nutrition 2001; 17: 438-442
11. Wilcock A. Anorexia: a taste of things to come? Palliat Med 2006; 20: 43-45
12. Mitch WE. Cachexia in chronic kidney disease: a link to defective central nervous system control of appetite. J Clin Invest 2005; 115: 1476-1478
13. Kotler DP. Cachexia. Ann Intern Med 2000; 133: 622-634
14. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2: 862-871
15. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest 1999; 115: 836-847
16. Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050-1053
17. Fearon KC, Von Meyenfeldt MF, Moses AG et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003; 52: 1479-1486
18. Lorite MJ, Smith HJ, Arnold JA et al. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer 2001; 85: 297-302
19. Tisdale MJ. Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci 2001; 6: D164-D174
20. Costelli P, Baccino FM. Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care 2003; 6: 407-412
21. Ripamonti C. Management of dyspnea in advanced cancer patients. Support Care Cancer 1999; 7: 233-243
22. Dewys WD. Anorexia as a general effect of cancer. Cancer 1979; 43: 2013-2019
23. Wigmore SJ, Plester CE, Ross JA et al. Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg 1997; 84: 196-197
24. Argiles JM, Moore-Carrasco R, Busquets S et al. Catabolic mediators as targets for cancer cachexia. Drug Discov Today 2003; 8: 838-844
25. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999; 59: 4493-4501
26. Barber MD, Fearon KC, Tisdale MJ et al. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer 2001; 40: 118-124
27. van Cutsem E, Arends J. The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 2005; 9 (Suppl 2): S51-S63
28. Argiles JM, Meijsing SH, Pallares-Trujillo J et al. Cancer cachexia: a therapeutic approach. Med Res Rev 2001; 21: 83-101
29. Inui A, Meguid MM. Cachexia and obesity: two sides of one coin? Curr Opin Clin Nutr Metab Care 2003; 6: 395-399
30. Nelson KA. Modern management of the cancer anorexia-cachexia syndrome. Curr Oncol Rep 2000; 2: 362-368
31. Nelson KA, Walsh D. The cancer anorexia-cachexia syndrome: a survey of the Prognostic Inflammatory and Nutritional Index (PINI) in advanced disease. J Pain Symptom Manage 2002; 24: 424-428
32. Argiles JM, Almendro V, Busquets S et al. The pharmacological treatment of cachexia. Curr Drug Targets 2004; 5: 265-277
33. Davidson W, Ash S, Capra S et al. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr 2004; 23: 239-247
34. Martignoni ME, Kunze P, Friess H. Cancer cachexia. Mol Cancer 2003; 2: 36
35. Barber MD, McMillan DC, Wallace AM et al. The response of leptin, interleukin-6 and fat oxidation to feeding in weight-losing patients with pancreatic cancer. Br J Cancer 2004; 90: 1129-1132
36. Falconer JS, Fearon KC, Plester CE et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219: 325-331
37. Tisdale MJ. The 'cancer cachectic factor'. Support Care Cancer 2003; 11: 73-78
38. Bosaeus I, Daneryd P, Svanberg E et al. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer 2001; 93: 380-383
39. Wigmore SJ, Falconer JS, Plester CE et al. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 1995; 72: 185-188
40. Harvie MN, Campbell IT. Energy balance, cancer and the sympathetic nervous system. Eur J Cancer 2000; 36: 289-292
41. Young VR. Energy metabolism and requirements in the cancer patient. Cancer Res 1977; 37: 2336-2347
42. Inui A. Neuropeptide Y: a key molecule in anorexia and cachexia in wasting disorders? Mol Med Today 1999; 5: 79-85
43. Argiles JM, Busquets S, Lopez-Soriano FJ. Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 2003; 6: 401-406
44. Palesty JA, Dudrick SJ. What we have learned about cachexia in gastrointestinal cancer. Dig Dis 2003; 21: 198-213
45. Gordon JN, Green SR, Goggin PM. Cancer cachexia. QJM 2005; 98: 779-788
46. Barber MD. Cancer cachexia and its treatment with fish-oil-enriched nutritional supplementation. Nutrition 2001; 17: 751-755
47. Moldawer LL, Copeland III EM. Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer 1997; 79: 1828-1839
48. Esper DH, Harb WA. The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr Clin Pract 2005; 20: 369-376
49. Mantovani G, Maccio A, Massa E et al. Managing cancer-related anorexia/cachexia. Drugs 2001; 61: 499-514
50. Ebrahimi B, Tucker SL, Li D et al. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004; 101: 2727-2736
51. Martignoni ME, Kunze P, Hildebrandt W et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 2005; 11: 5802-5808
52. Falconer JS, Fearon KC, Ross JA et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995; 75: 2077-2082
53. Batterham RL, Cowley MA, Small CJ et al. Gut hormone PYY(3 - 36) physiologically inhibits food intake. Nature 2002; 418: 650-654
54. Tisdale MJ. Biochemical mechanisms of cellular catabolism. Curr Opin Clin Nutr Metab Care 2002; 5: 401-405
55. Smith HJ, Tisdale MJ. Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes. Br J Cancer 2003; 89: 1783-1788
56. Gomes-Marcondes MC, Smith HJ, Cooper JC et al. Development of an invitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor. Br J Cancer 2002; 86: 1628-1633
57. Tisdale MJ. Metabolic abnormalities in cachexia and anorexia. Nutrition 2000; 16: 1013-1014
58. Cabal-Manzano R, Bhargava P, Torres-Duarte A et al. Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer 2001; 84: 1599-1601
59. Watchorn TM, Waddell I, Dowidar N et al. Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB J 2001; 15: 562-564
60. Watchorn TM, Waddell I, Ross JA. Proteolysis-inducing factor differentially influences transcriptional regulation in endothelial subtypes. Am J Physiol Endocrinol Metab 2002; 282: E763-E769
61. Whitehouse AS, Tisdale MJ. Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. Br J Cancer 2003; 89: 1116-1122
62. Lecker SH, Solomon V, Mitch WE et al. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999; 129: 227S-237S
63. Khal J, Wyke SM, Russell ST et al. Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br J Cancer 2005: 1-7
64. Voisin L, Breuille D, Combaret L et al. Muscle wasting in a rat model of long-lasting sepsis results from the activation of lysosomal, Ca2+-activated, and ubiquitin-proteasome proteolytic pathways. J Clin Invest 1996; 97: 1610-1617
65. O'Riordain MG, Falconer JS, Maingay J et al. Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism. Int J Oncol 1999; 15: 823-827
66. Wigmore SJ, Ross JA, Falconer JS et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996; 12: S27-S30
67. Wigmore SJ, Todorov PT, Barber MD et al. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 2000; 87: 53-58
68. Bauer J, Capra S, Battistuta D et al. Compliance with nutrition prescription improves outcomes in patients with unresectable pancreatic cancer. Clin Nutr 2008; 24: 998-1004
69. Willox JC, Corr J, Shaw J et al. Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 1984; 288: 27
70. Bruera E, Ernst S, Hagen N et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998; 2: 74-78
71. Vadell C, Segui MA, Gimenez-Arnau JM et al. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol 1998; 21: 347-351
72. Loprinzi CL, Schaid DJ, Dose AM et al. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993; 11: 152-154
73. Strasser F, Luftner D, Possinger K et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006; 24: 3394-3400
74. Stephens TW, Basinski M, Bristow PK et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995; 377: 530-532
75. Pascual LA, Figuls M, Urrutia CG et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004; 27: 360-369
76. Endres S, Ghorbani R, Kelley VE et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265-271
77. Wigmore SJ, Fearon KC, Maingay JP et al. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 1997; 92: 215-221
78. Jho DH, Cole SM, Lee EM et al. Role of omega-3 fatty acid supplementation in inflammation and malignancy. Integr Cancer Ther 2004; 3: 98-111
79. Fearon KC, Barber MD, Moses AG et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006; 24: 3401-3407
80. Gordon JN, Trebble TM, Ellis RD et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54: 540-545
81. Goldberg RM, Loprinzi CL, Mailliard JA et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995; 13: 2856-2859
82. McMillan DC, Wigmore SJ, Fearon KC et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999; 79: 495-500
83. McMillan DC, O'Gorman P, Fearon KC et al. A pilot study of megestrol acetate and Ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer 1997; 76: 788-790
84. Neoptolemos J, Dunn J, Stocken D et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576-1585
85. Park J, Ryu J, Lee J et al. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas 2006; 33: 397-402
86. Park J, Yoon Y, Kim Y et al. Survival and prognostic factors of unresectable pancreatic cancer. J Clin Gastroenterol 2008; 42: 86-91
87. Oettle H, Neuhaus P. Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs 2007; 67: 2293-2310
88. Fisher B, Perera F, Kocha W et al. Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008; 45: 291-295
89. Michalski C, Kleeff J, Jaeger D et al. Adjuvant treatment of pancreatic cancer. Dtsch med Wochenschr 2007; 132: 803-807
90. Melstrom L, Melstrom KJ, Ding X et al. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histology and Histopathology 2007; 22: 805-814
91. Smith HJ, Lorite MJ, Tisdale MJ. Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid. Cancer research 1999; 59: 5507-5513
92. Tisdale MJ. Wasting in cancer. The Journal of Nutrition 1999; 129: 243S-246S